Methylergonovine
Methergine, Methylergonovine (methylergonovine) is a small molecule pharmaceutical. Methylergonovine was first approved as Methergine on 1982-01-01. It is used to treat postpartum hemorrhage in the USA. It is known to target 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1F, and 5-hydroxytryptamine receptor 2B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Methergine, Methylergonovine (discontinued: Methergine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methylergonovine maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| METHERGINE | Edison Pharmaceuticals | N-006035 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| methergine | ANDA | 2024-03-20 |
| methylergonovine maleate | ANDA | 2024-09-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postpartum hemorrhage | — | D006473 | O72 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2210 | Injection, methylergonovine maleate, up to 0.2 mg |
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | 6 | 2 | 9 |
| Postpartum hemorrhage | D006473 | — | O72 | 1 | — | — | 4 | 1 | 6 |
| Uterine inertia | D014593 | EFO_1001863 | O62.2 | 1 | — | — | 3 | 1 | 5 |
| Cesarean section | D002585 | — | — | 1 | — | — | 1 | — | 2 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 1 | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | 1 | — | 1 |
| Pregnancy complications | D011248 | — | — | — | — | — | 1 | — | 1 |
| Twin pregnancy | D059285 | — | O30.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dystocia | D004420 | EFO_1000911 | O66.9 | — | — | — | — | 1 | 1 |
| Endometritis | D004716 | EFO_1001312 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methylergonovine |
| INN | methylergometrine |
| Description | (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide is an ergoline alkaloid. |
| Classification | Small molecule |
| Drug class | ergot alkaloid deriviatives; vinca alkaloids |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1 |
Identifiers
| PDB | — |
| CAS-ID | 113-42-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201356 |
| ChEBI ID | — |
| PubChem CID | 8226 |
| DrugBank | DB00353 |
| UNII ID | W53L6FE61V (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Methylergonovine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,013 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
758 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use